<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Varex Imaging Corporation

    Varex Imaging Corporation

    We are a leading innovator and manufacturer of X-ray imaging components, including...

    We are a leading innovator and manufacturer of ...

    Filing Type:    PU
    Adaptive Biotechnologies Corporation

    Adaptive Biotechnologies Corporation

    We are a commercial-stage biotech company focused on harnessing the inherent biolo...

    We are a commercial-stage biotech company focus...

    Filing Type:    PU
    Reata Pharmaceuticals, Inc.

    Reata Pharmaceuticals, Inc.

    Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...

    Reata is a clinical-stage biopharmaceutical com...

    Filing Type:    PU
    Allakos Inc.

    Allakos Inc.

    Allakos is a clinical-stage company developing therapeutic antibodies that selecti...

    Allakos is a clinical-stage company developing ...

    Filing Type:    PU
    Seres Therapeutics, Inc.

    Seres Therapeutics, Inc.

    Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...

    Seres Therapeutics, Inc. is a microbiome therap...

    Filing Type:    PU
    Emerald Health Pharmaceuticals Inc

    Emerald Health Pharmaceuticals Inc

    Emerald Health Pharmaceuticals (EHP) combines decades of life science and drug dev...

    Emerald Health Pharmaceuticals (EHP) combines d...

    Amount Raised:    11.600,000.00
    Fundraising Status:    EC
    Filing Type:    RA
    Global Cancer Technology, Inc

    Global Cancer Technology, Inc

    Global Cancer Technology (“GCT”) is an emerging medical technology company with nu...

    Global Cancer Technology (“GCT”) is an emerging...

    Amount Raised:    $82,711.00
    Fundraising Status:    EC
    Filing Type:    CF
    Evelo Biosciences, Inc.

    Evelo Biosciences, Inc.

    Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...

    Evelo Biosciences, Inc. is a clinical stage bio...

    Filing Type:    PU
    Vaccinex, Inc.

    Vaccinex, Inc.

    Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...

    Vaccinex is a clinical-stage biotechnology comp...

    Filing Type:    PU
    Provention Bio, Inc.

    Provention Bio, Inc.

    Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...

    Provention Bio, Inc. is a clinical-stage biopha...

    Filing Type:    PU
    Forward Pharma A/S

    Forward Pharma A/S

    Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...

    Forward Pharma A/S is a Danish biopharmaceutica...

    Filing Type:    PU
    Enlivex Therapeutics Ltd.

    Enlivex Therapeutics Ltd.

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...

    Enlivex is a clinical stage immunotherapy compa...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.